Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position
Psyence Biomedical ( (PBM) ) has provided an announcement. Psyence Biomedical Ltd. has regained compliance with all Nasdaq continued listing requirements after transferring from The Nasdaq Global Market to The Nasdaq Capital Market. This was achieved through a 75-for-1 share consolidation, meeting the $1 minimum bid price requirement. With a debt-free balance sheet and $5.6 million in cash, the company is now well-positioned to advance its business plans and clinical trials, having begun patient